Sprint Bioscience AB (publ) (SPRINT.ST)
SEK 0.65
(-5.8%)
SEK 0.65
(-5.8%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.08 Million SEK | 94.55% |
| 2022 | -59.99 Million SEK | -148.89% |
| 2021 | -24.49 Million SEK | 37.33% |
| 2020 | -38.05 Million SEK | -97.24% |
| 2019 | -19.58 Million SEK | 8.32% |
| 2018 | -31.06 Million SEK | -112.54% |
| 2017 | -10.05 Million SEK | -192.73% |
| 2016 | 5.07 Million SEK | 171.6% |
| 2015 | -15.14 Million SEK | -39.37% |
| 2014 | -10.86 Million SEK | -182.51% |
| 2013 | -3.84 Million SEK | 25.53% |
| 2012 | -5.16 Million SEK | -237.43% |
| 2011 | -1.53 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -5.1 Million SEK | -93.64% |
| 2024 Q3 | -4.87 Million SEK | 14.09% |
| 2024 Q1 | -3.57 Million SEK | 43.17% |
| 2023 Q2 | -11.6 Million SEK | 4.36% |
| 2023 Q3 | 28.7 Million SEK | 347.29% |
| 2023 Q1 | -12.13 Million SEK | 18.22% |
| 2023 Q4 | -4.92 Million SEK | -117.15% |
| 2023 FY | - SEK | 94.55% |
| 2022 FY | - SEK | -148.89% |
| 2022 Q3 | -13.1 Million SEK | 26.19% |
| 2022 Q2 | -17.75 Million SEK | -26.43% |
| 2022 Q4 | -14.83 Million SEK | -13.24% |
| 2022 Q1 | -14.04 Million SEK | 5.85% |
| 2021 FY | - SEK | 37.33% |
| 2021 Q4 | -14.91 Million SEK | -182.8% |
| 2021 Q3 | 18.01 Million SEK | 231.28% |
| 2021 Q2 | -13.72 Million SEK | -8.18% |
| 2021 Q1 | -12.68 Million SEK | 11.85% |
| 2020 Q1 | -9.13 Million SEK | 9.77% |
| 2020 FY | - SEK | -97.24% |
| 2020 Q4 | -14.39 Million SEK | -184.29% |
| 2020 Q2 | -9.88 Million SEK | -8.23% |
| 2020 Q3 | -5.06 Million SEK | 48.81% |
| 2019 Q3 | -8.02 Million SEK | -259.27% |
| 2019 FY | - SEK | 8.32% |
| 2019 Q4 | -10.12 Million SEK | -26.18% |
| 2019 Q2 | 5.03 Million SEK | 177.81% |
| 2019 Q1 | -6.47 Million SEK | 38.86% |
| 2018 Q4 | -10.59 Million SEK | -21.61% |
| 2018 FY | - SEK | -112.54% |
| 2018 Q3 | -8.7 Million SEK | 8.72% |
| 2018 Q2 | -9.54 Million SEK | -227.79% |
| 2018 Q1 | 7.46 Million SEK | 205.39% |
| 2017 Q1 | 1.21 Million SEK | -58.13% |
| 2017 Q2 | 1.13 Million SEK | -6.49% |
| 2017 Q3 | -5.33 Million SEK | -568.66% |
| 2017 Q4 | -7.08 Million SEK | -32.71% |
| 2017 FY | - SEK | -192.73% |
| 2016 Q2 | 7.11 Million SEK | 362.26% |
| 2016 FY | - SEK | 171.6% |
| 2016 Q4 | 2.9 Million SEK | 344.83% |
| 2016 Q3 | 654 Thousand SEK | -90.8% |
| 2016 Q1 | -2.71 Million SEK | 30.76% |
| 2015 FY | - SEK | -39.37% |
| 2015 Q4 | -3.91 Million SEK | -55.25% |
| 2015 Q3 | -2.52 Million SEK | 49.12% |
| 2015 Q2 | -4.95 Million SEK | -32.08% |
| 2015 Q1 | -3.75 Million SEK | -5.03% |
| 2014 Q4 | -3.57 Million SEK | -39.97% |
| 2014 FY | - SEK | -182.51% |
| 2014 Q1 | -2.27 Million SEK | -269.97% |
| 2014 Q2 | -2.46 Million SEK | -8.03% |
| 2014 Q3 | -2.55 Million SEK | -3.7% |
| 2013 Q3 | -1.24 Million SEK | -25.93% |
| 2013 Q2 | -991 Thousand SEK | 0.0% |
| 2013 Q4 | -616 Thousand SEK | 50.64% |
| 2013 FY | - SEK | 25.53% |
| 2013 Q1 | -991 Thousand SEK | 0.0% |
| 2012 FY | - SEK | -237.43% |
| 2011 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 99.434% |
| Camurus AB (publ) | 562.54 Million SEK | 100.37% |
| Mendus AB (publ) | -97.84 Million SEK | 97.874% |
| Lipum AB (publ) | -37.11 Million SEK | 94.396% |
| NextCell Pharma AB | -40.98 Million SEK | 94.925% |
| Simris Alg AB (publ) | -22.36 Million SEK | 90.699% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | 87.825% |
| Active Biotech AB (publ) | -43.88 Million SEK | 95.261% |
| Amniotics AB (publ) | -27.14 Million SEK | 92.337% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | 85.37% |
| BioArctic AB (publ) | 275.38 Million SEK | 100.755% |
| Cantargia AB (publ) | -284.31 Million SEK | 99.268% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 89.376% |
| CombiGene AB (publ) | -35.33 Million SEK | 94.114% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 98.523% |
| Genovis AB (publ.) | 64.57 Million SEK | 103.221% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 98.19% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 94.382% |
| Intervacc AB (publ) | -68.98 Million SEK | 96.985% |
| Kancera AB (publ) | -61.88 Million SEK | 96.639% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 92.234% |
| LIDDS AB (publ) | -39.67 Million SEK | 94.757% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | 82.816% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 106.623% |
| OncoZenge AB (publ) | 7.26 Million SEK | 128.626% |
| Saniona AB (publ) | -69.69 Million SEK | 97.016% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 99.345% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 99.262% |
| Xintela AB (publ) | -53.47 Million SEK | 96.11% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 98.775% |
| Ziccum AB (publ) | -20.34 Million SEK | 89.775% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 104100.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 99.125% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | 84.513% |
| Corline Biomedical AB | -1.69 Million SEK | -23.004% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 98.8% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 96.205% |
| Aptahem AB (publ) | -10 Million SEK | 79.219% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 118.01% |
| Fluicell AB (publ) | -25.91 Million SEK | 91.973% |
| Biovica International AB (publ) | -119.5 Million SEK | 98.26% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 95.074% |
| AcouSort AB (publ) | -16.7 Million SEK | 87.547% |
| Abliva AB (publ) | -93.6 Million SEK | 97.778% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 99.348% |
| 2cureX AB (publ) | -35.13 Million SEK | 94.08% |
| I-Tech AB | 30.34 Million SEK | 106.855% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 99.709% |
| Cyxone AB (publ) | -20.41 Million SEK | 89.811% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 97.97% |
| Biosergen AB | 228 Thousand SEK | 1012.281% |
| Nanologica AB (publ) | -62.11 Million SEK | 96.652% |
| SynAct Pharma AB | -222.7 Million SEK | 99.066% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 95.258% |
| BioInvent International AB (publ) | -312.7 Million SEK | 99.335% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 772.241% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 5052.499% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 99.102% |
| Pila Pharma AB (publ) | -8.81 Million SEK | 76.397% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 98.084% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | 81.864% |